Position
Renaissance Technologies in C4 Therapeutics, Inc.
Back to the book · All holders of CCCC
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $2.43M$2.63 → $4.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.6M | $3.06M | — | — | — | 0.0% |
| Q1 2026 | 2.46M | $6.47M | $2.63 | $1.15M | $2.26M | 0.0% |
| Q2 2026 | 1.19M | $5.56M | $4.67 | $2.43M | −$3.35M | 0.0% |